The major therapeutic intervention of S1P signaling in cancer focuses on: (i) inhibition of SK1 activity; (ii) antagonism of S1P1/3 receptors; and (iii) reduction in S1P bioavailability. This evidence concerns the gene S1PR1 and cancer.